Payment overview · 2025
General Payments
$1,725.88
102 reported records · 18 companies
Healthcare provider profile · identity verified
Athmaram Shetty, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1164416145
Verified facts
What the public records show
CMS Open Payments records show Athmaram Shetty, M.D. received $1,725.88 in general payments during 2025 across 102 reported records.
Lilly USA, LLC accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $292.43 | 16.9% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $251.18 | 14.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $236.85 | 13.7% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.19 | 9.9% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.32 | 7.9% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.95 | 4.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $80.78 | 4.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.28 | 4.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.54 | 3.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.17 | 3.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.91 | 3.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.03 | 2.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.07 | 2.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.97 | 2.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.57 | 1.5% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $20.69 | 1.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.30 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.65 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,725.88 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $158.47 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.38 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $150.30 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $145.47 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.71 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.95 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $112.17 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.35 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $98.24 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $97.18 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $97.18 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $92.65 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $80.95 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $80.78 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.38 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.00 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.54 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.17 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.21 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.21 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.21 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $43.67 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.63 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
71 | 70 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 902 | 238 |
| Levothyroxine Sodium | Levothyroxine Sodium | 686 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 168 |
| Lisinopril | Lisinopril | 509 | 132 |
| Losartan Potassium | Losartan Potassium | 473 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 120 |
| Omeprazole | Omeprazole | 406 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 384 | 109 |
| Alprazolam | Alprazolam | 383 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 104 |
| Simvastatin | Simvastatin | 377 | 91 |
| Sertraline Hcl | Sertraline Hcl | 331 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 323 | 81 |
| Metformin Hcl Er | Metformin Hcl | 294 | 80 |
| Gabapentin | Gabapentin | 289 | 72 |
| Tramadol Hcl | Tramadol Hcl | 254 | 73 |
| Montelukast Sodium | Montelukast Sodium | 246 | 59 |
| Metformin Hcl | Metformin Hcl | 238 | 63 |
| Furosemide | Furosemide | 237 | 76 |
| Eliquis | Apixaban | 229 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 57 |
| Meloxicam | Meloxicam | 225 | 67 |
| Potassium Chloride | Potassium Chloride | 217 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 211 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 67 |
| Trazodone Hcl | Trazodone Hcl | 207 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 52 |
| Allopurinol | Allopurinol | 189 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 175 | 50 |
| Famotidine | Famotidine | 174 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 41 |
| Glimepiride | Glimepiride | 148 | 36 |
| Lorazepam | Lorazepam | 139 | 32 |
| Atenolol | Atenolol | 137 | 34 |
| Prednisone | Prednisone | 136 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 131 | 33 |
| Alendronate Sodium | Alendronate Sodium | 128 | 36 |
| Donepezil Hcl | Donepezil Hcl | 127 | 28 |
| Finasteride | Finasteride | 124 | 32 |
| Mirtazapine | Mirtazapine | 122 | 24 |
| Azithromycin | Azithromycin | 110 | 94 |
| Buspirone Hcl | Buspirone Hcl | 107 | 35 |
| Spironolactone | Spironolactone | 104 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 26 |
| Pregabalin | Pregabalin | 103 | 25 |
| Lovastatin | Lovastatin | 102 | 28 |
| Enalapril Maleate | Enalapril Maleate | 101 | 28 |
| Clonazepam | Clonazepam | 99 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 24 |
| Jardiance | Empagliflozin | 95 | 20 |
| Methocarbamol | Methocarbamol | 95 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 20 |
| Torsemide | Torsemide | 93 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 26 |
| Carvedilol | Carvedilol | 83 | 25 |
| Ezetimibe | Ezetimibe | 80 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 30 |
| Mounjaro | Tirzepatide | 76 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 71 | 70 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 69 | 29 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 58 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 16 |
| Bupropion Xl | Bupropion Hcl | 61 | 17 |
| Cefdinir | Cefdinir | 61 | 55 |
| Januvia | Sitagliptin Phosphate | 57 | 13 |
| Diazepam | Diazepam | 56 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 15 |
| Ozempic | Semaglutide | 49 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 12 |
| Nabumetone | Nabumetone | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | 12 |
| Amoxicillin | Amoxicillin | 44 | 35 |
| Glipizide | Glipizide | 43 | 11 |
| Temazepam | Temazepam | 43 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Clonidine Hcl | Clonidine Hcl | 41 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 11 |
| Celecoxib | Celecoxib | 40 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 11 |
| Ibuprofen | Ibuprofen | 40 | 12 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 11 |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 12 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Indapamide | Indapamide | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 25 |
| Levofloxacin | Levofloxacin | 29 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 20 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,725.88 · 102 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, Prospera, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error